In a study of CD19-specific CAR T cell treatment in children with relapsed or refractory ALL, 93% complete remission at one month after infusion and ~58% complete remission at a median follow up of 12 months after infusion were reported [102]. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.